86 results
Page 2 of 5
6-K
EX-99.1
utsgmvq duxckgt
3 Oct 22
Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies
6:02pm
6-K
EX-99.1
cofneq gvqcak1c7h
8 Aug 22
First key steps in pipeline rebuild and strong commercial progress in H1 2022
4:59pm
6-K
EX-99.2
zl90a5q0
8 Aug 22
First key steps in pipeline rebuild and strong commercial progress in H1 2022
4:59pm
6-K
EX-99.2
16a3yg
6 May 22
Current report (foreign)
5:18pm
6-K
EX-99.1
3tp0c0qs8
24 Feb 22
Galapagos 2021 results set stage for future growth
5:19pm
6-K
EX-99.1
l7b3raq
7 Feb 22
Current report (foreign)
2:40pm
6-K
EX-99.2
4faazcokz6cmhln22
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
6-K
EX-99.1
usswtkr
6 Oct 21
Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
6:00am
6-K
EX-99.1
ivsvbpd2sxpigqnfid
6 Oct 21
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
6:00am
6-K
EX-99.2
q6ky6lrl
5 Aug 21
Galapagos reports H1 financial results with refocused pipeline and operational progress
4:02pm
6-K
EX-99.1
b3d8wvqqez v705d3
5 Aug 21
Galapagos reports H1 financial results with refocused pipeline and operational progress
4:02pm
6-K
EX-99.1
qo9q9hr efu
14 Jul 21
Current report (foreign)
5:27pm
6-K
EX-99.1
gaoo0g qgh
14 Jul 21
Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study
5:13pm
6-K
EX-99.1
ywfoq7edmuhvm2odh8rn
12 Jul 21
New post-hoc analyses of data from SELECTION Phase 3 program presented at European Crohn’s and Colitis Organisation (ECCO) virtual congress
9:02am
6-K
EX-99.2
orib9m9e
11 May 21
Current report (foreign)
2:10pm
6-K
EX-99.3
zauz8pbru
11 May 21
Current report (foreign)
2:10pm
6-K
EX-99.1
1dshowi0lfxf 8s
15 Dec 20
Current report (foreign)
4:55pm
6-K
EX-99.2
ytt0l9lr
9 Nov 20
Galapagos reports Q3 2020 results
4:01pm